Site Editor

Thomas Flaig, MD


Novel Gene Signature for Bladder Cancer: Predicting Prognosis and Therapeutic Response

By: Joshua Swore, PhD
Posted: Wednesday, May 3, 2023

A novel gene signature based on tumor-infiltrating lymphocyte (TIL)-related genes may be used to predict overall survival and classify patient outcome and immune profile, according to a research article published in BMC Bioinformatics. “Tumor-infiltrating lymphocytes in primary bladder tumors and lymph nodes can be extracted from patients, multiplied, and show antitumor activity in vitro,” said Li and Xie, of Sun Yat-Sen University, Guangzhou, China. “Exploration of genes associated with tumor-infiltrating lymphocytes is therefore essential to comprehending bladder cancer treatment and prognosis."

The study used RNA sequencing and clinical data downloaded from The Cancer Genome Atlas and gene-expression omnibus databases to investigate TIL-related gene signatures in bladder cancer. A total of 410 bladder tumor samples and 19 control bladder samples were used in the study. TIL-related gene signatures were evaluated using the Pearson correlation analysis, and hub TIL-related gene signatures were selected through comprehensive analysis. Patient data from The Cancer Genome Atlas were then divided into different clusters based on the hub TIL-related gene signatures to explore the immune landscape between different clusters.

The authors reported five hub TIL-related gene signatures, and two patient clusters were identified. Each group had a different prognosis, clinical characteristics, tumor microenvironment, immune cell infiltration, drug sensitivity, and immunotherapy responses. The model indicated that the low-risk group had better clinical results and greater immunotherapy sensitivity. The unsupervised clustering analysis based on the five hub TIL-related gene signatures identified two molecular subtypes in TIL-related gene signatures, each with a different prognosis, clinical outcome, and immune landscape. Lastly, the authors noted this model may be used to help identify therapeutic targets for patients with bladder cancer.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.